Skip to main content
Premium Trial:

Request an Annual Quote

Berkeley Lights Prices Upsized $178.2M IPO

NEW YORK – Berkeley Lights announced Thursday it expects to raise $178.2 million in an upsized initial public offering priced above the expected range.

The maker of instruments for cell engineering said in a statement it will offer 8.1 million shares of common stock at $22 per share. Previously the firm had said it would offer 7.4 million shares at an estimated price of $16 to $18 per share.

Berkeley Lights has granted the underwriters a 30-day option to purchase up to an additional 1,215,000 shares of stock at the IPO price, less the underwriting discounts and commissions. JP Morgan, Morgan Stanley, and Cowen are acting as lead book-running managers for the offering. William Blair is acting as a co-manager.

Based in Emeryville, California, Berkeley Lights offers the Beacon Optofluidic System, a platform for finding cells of interest.

Shares of Berkeley Lights will trade on the Nasdaq under ticker symbol BLI. The offering is expected to close on July 21, subject to customary closing conditions.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.